/ NOVO
/ Market Analysis
Why Did HIMS Shares Crash Today? Novo Nordisk Terminates Deal Over “Deceptive” Practices
Novo Nordisk ended its month-old partnership with Hims & Hers Health over illegal drug compounding practices.
June 23, 2025
Novo Nordisk’s Shares Dip Amid Surprise CEO Exit in Challenging Times for the Firm
Novo Nordisk's surprise CEO departure amid mounting competitive pressures and disappointing clinical results has accelerated the stock's 50% decline since mid-2024.
May 16, 2025
NVO vs LLY: Which Pharma Stock is Likely to Do Better in 2025?
Obesity market continues to boom, with Novo Nordisk opening the gates wide open with Wegovy.
May 13, 2025
Eli Lilly Enters the Chinese Market as Tirzepatide Gains Approval, Shares Gain
Eli Lilly's weight loss drug tirzepatide has received approval from Chinese regulators, intensifying competition with Novo Nordisk.
July 19, 2024
Back to 
